Cocrystal Pharma, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Zacks Small Cap Forecasts (NASDAQ:COCP)

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Zacks Small Cap issued their Q3 2024 earnings per share estimates for Cocrystal Pharma in a research report issued on Tuesday, April 23rd. Zacks Small Cap analyst D. Bautz expects that the company will post earnings per share of ($0.59) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($2.31) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s FY2026 earnings at ($2.58) EPS.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.13.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Cocrystal Pharma in a research report on Thursday, April 4th.

Cocrystal Pharma Stock Up 3.0 %

NASDAQ:COCP opened at $1.56 on Thursday. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.29. The firm has a market cap of $15.82 million, a P/E ratio of -0.78 and a beta of 1.34. The business’s 50-day moving average price is $1.49 and its 200 day moving average price is $1.63.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.